Small‐Molecule Modulators for Epigenetics Targets

A capital conference: Influencing epigenetic mechanisms may be highly relevant for future therapies of various diseases such as cancer, inflammation, and metabolic disorders. Leading experts in the field gathered in Berlin on June 5-6, 2013 at a Bayer HealthCare Life Science Workshop to share recent success stories and to discuss future trends.

[1]  P. Bamborough,et al.  Discovery and characterization of small molecule inhibitors of the BET family bromodomains. , 2011, Journal of medicinal chemistry.

[2]  Takayoshi Suzuki,et al.  Lysine demethylases inhibitors. , 2011, Journal of medicinal chemistry.

[3]  I. Kovalchuk,et al.  Epigenetic control of plant stress response , 2008, Environmental and molecular mutagenesis.

[4]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[5]  Jian Jin,et al.  An allosteric inhibitor of protein arginine methyltransferase 3. , 2012, Structure.

[6]  A. Ferguson-Smith,et al.  Epigenetic regulation of the neural transcriptome: the meaning of the marks , 2010, Nature Neuroscience.

[7]  Andrew J. Woodhead,et al.  Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function , 2012, Nature chemical biology.

[8]  Tim J. Wigle,et al.  Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L , 2012, Chemical biology & drug design.

[9]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[10]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[11]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[12]  Feng Liu,et al.  A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. , 2011, Nature chemical biology.

[13]  Matthieu Schapira,et al.  Strategy to Target the Substrate Binding site of SET Domain Protein Methyltransferases , 2013, J. Chem. Inf. Model..

[14]  S. Knapp,et al.  Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands , 2013, Journal of medicinal chemistry.

[15]  T. Somervaille,et al.  LSD1 inhibition: a therapeutic strategy in cancer? , 2012, Expert opinion on therapeutic targets.

[16]  David M. Wilson,et al.  Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.

[17]  B. Fierz,et al.  Chromatin as an expansive canvas for chemical biology. , 2012, Nature chemical biology.

[18]  Steven J. Gamblin,et al.  Crystal Structure and Functional Analysis of the Histone Methyltransferase SET7/9 , 2002, Cell.

[19]  James M. Woolven,et al.  Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. , 2012, Journal of medicinal chemistry.

[20]  Robert A. Copeland,et al.  Protein methyltransferases as a target class for drug discovery , 2009, Nature Reviews Drug Discovery.

[21]  S. Müller,et al.  Epigenetic Chemical Probes , 2012, Clinical pharmacology and therapeutics.

[22]  M. Bunnage.  Getting pharmaceutical R&D back on target. , 2011, Nature chemical biology.

[23]  S. Frye,et al.  Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. , 2013, Journal of medicinal chemistry.

[24]  S. Wetzel,et al.  Impairment of prostate cancer cell growth by a selective and reversible lysine‐specific demethylase 1 inhibitor , 2012, International journal of cancer.

[25]  S. Frye,et al.  Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. , 2011, Journal of medicinal chemistry.

[26]  S. Knapp,et al.  PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. , 2013, Cancer research.

[27]  N. Keen,et al.  Structural basis of substrate methylation and inhibition of SMYD2. , 2011, Structure.

[28]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[29]  R. Copeland,et al.  Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics , 2012, Oncogene.

[30]  M. Esteller,et al.  Epigenetic modifications and human disease , 2010, Nature Biotechnology.

[31]  G. Poda,et al.  Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5 , 2012, The Biochemical journal.

[32]  Peter A. Jones,et al.  Epigenetic Modifications as Therapeutic Targets , 2010, Nature Biotechnology.

[33]  Paul D. Leeson,et al.  The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.

[34]  Valérie Campagna-Slater,et al.  Structural Chemistry of the Histone Methyltransferases Cofactor Binding Site , 2011, J. Chem. Inf. Model..

[35]  S. Knapp,et al.  Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit , 2012, Journal of medicinal chemistry.

[36]  Lihua Liu,et al.  ChromoHub: a data hub for navigators of chromatin-mediated signalling , 2012, Bioinform..

[37]  B. Fierz,et al.  Stability of nucleosomes containing homogenously ubiquitylated H2A and H2B prepared using semisynthesis. , 2012, Journal of the American Chemical Society.

[38]  Robert A Copeland,et al.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.

[39]  C. Zahnow,et al.  The future of epigenetic therapy in solid tumours—lessons from the past , 2013, Nature Reviews Clinical Oncology.

[40]  K. Hahn,et al.  An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. , 2013, ACS chemical biology.

[41]  Robert A. Copeland,et al.  Protein methyltransferase inhibitors as personalized cancer therapeutics , 2012 .

[42]  L. Altucci,et al.  Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors , 2011, ChemMedChem.

[43]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.